- Home
- ZNTL vs RAPT Comparison
ZNTL vs RAPT Comparison
Compare ZNTL & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- RAPT
- Stock Information
- Founded
- ZNTL 2014
- RAPT 2015
- Country
- ZNTL United States
- RAPT United States
- Employees
- ZNTL N/A
- RAPT N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ZNTL Health Care
- RAPT Health Care
- Exchange
- ZNTL Nasdaq
- RAPT Nasdaq
- Market Cap
- ZNTL 105.8M
- RAPT 117.5M
- IPO Year
- ZNTL 2020
- RAPT 2019
- Fundamental
- Price
- ZNTL $1.32
- RAPT $7.35
- Analyst Decision
- ZNTL Buy
- RAPT Buy
- Analyst Count
- ZNTL 7
- RAPT 5
- Target Price
- ZNTL $8.60
- RAPT $42.00
- AVG Volume (30 Days)
- ZNTL 961.9K
- RAPT 120.8K
- Earning Date
- ZNTL 08-08-2025
- RAPT 08-07-2025
- Dividend Yield
- ZNTL N/A
- RAPT N/A
- EPS Growth
- ZNTL N/A
- RAPT N/A
- EPS
- ZNTL N/A
- RAPT N/A
- Revenue
- ZNTL $26,865,000.00
- RAPT N/A
- Revenue This Year
- ZNTL N/A
- RAPT N/A
- Revenue Next Year
- ZNTL N/A
- RAPT N/A
- P/E Ratio
- ZNTL N/A
- RAPT N/A
- Revenue Growth
- ZNTL N/A
- RAPT N/A
- 52 Week Low
- ZNTL $1.01
- RAPT $5.67
- 52 Week High
- ZNTL $5.70
- RAPT $30.60
- Technical
- Relative Strength Index (RSI)
- ZNTL 47.15
- RAPT 43.57
- Support Level
- ZNTL $1.31
- RAPT $6.88
- Resistance Level
- ZNTL $1.54
- RAPT $8.91
- Average True Range (ATR)
- ZNTL 0.14
- RAPT 0.70
- MACD
- ZNTL -0.00
- RAPT -0.16
- Stochastic Oscillator
- ZNTL 31.36
- RAPT 11.36
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.